Sacubitril/Valsartan in “Field Practice” Patients with Advanced Heart Failure: A Monocentric Italian Experience
暂无分享,去创建一个
F. Achilli | A. Vincenzi | L. Garatti | F. Cesana | A. Ciró
[1] M. White,et al. Approach to advanced heart failure at the end of life. , 2017, Canadian family physician Medecin de famille canadien.
[2] Akshay S. Desai,et al. Angiotensin Receptor Neprilysin Inhibition in Heart Failure With Preserved Ejection Fraction: Rationale and Design of the PARAGON-HF Trial. , 2017, JACC. Heart failure.
[3] F. Fruhwald,et al. Advanced heart failure: an appraisal of the potential of levosimendan in this end-stage scenario and some related ethical considerations , 2016, Expert review of cardiovascular therapy.
[4] P. Shekar,et al. Current state-of-the-art of device therapy for advanced heart failure , 2014, Croatian medical journal.
[5] Akshay S. Desai,et al. Angiotensin-neprilysin inhibition versus enalapril in heart failure. , 2014, The New England journal of medicine.
[6] T. Langenickel,et al. Angiotensin receptor-neprilysin inhibition with LCZ696: a novel approach for the treatment of heart failure , 2012 .